Last reviewed · How we verify
epinephrine and levosimendan
This combination uses epinephrine's alpha and beta-adrenergic stimulation alongside levosimendan's calcium sensitization to enhance cardiac contractility and improve hemodynamics in acute heart failure.
This combination uses epinephrine's alpha and beta-adrenergic stimulation alongside levosimendan's calcium sensitization to enhance cardiac contractility and improve hemodynamics in acute heart failure. Used for Acute decompensated heart failure with cardiogenic shock, Acute heart failure requiring inotropic support.
At a glance
| Generic name | epinephrine and levosimendan |
|---|---|
| Sponsor | Federal University of Juiz de Fora |
| Drug class | Inotropic agent combination |
| Target | Adrenergic receptors (alpha-1, beta-1) and cardiac troponin C |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Epinephrine acts as a catecholamine agonist, increasing heart rate and contractile force through beta-1 adrenergic receptors while also providing vasoconstriction via alpha-1 receptors. Levosimendan is an inodilator that increases myocardial contractility by sensitizing cardiac troponin C to calcium without increasing oxygen consumption, while simultaneously causing vasodilation. Together, they provide both inotropic support and hemodynamic improvement in cardiogenic shock or acute decompensated heart failure.
Approved indications
- Acute decompensated heart failure with cardiogenic shock
- Acute heart failure requiring inotropic support
Common side effects
- Tachycardia
- Hypertension
- Arrhythmias
- Tremor
- Headache
Key clinical trials
- Multimodal Vasopressor Strategy in Septic Shock (PHASE2, PHASE3)
- Impact of Perioperative Levosimendan on Patients Undergoing Cardiac Surgery With Low Ejection Fraction (PHASE2)
- Study on Early Intra-aortic Balloon Pump Placement in Acute Decompensated Heart Failure Complicated by Cardiogenic Shock (PHASE4)
- Vasoactive-inotropic Support and Levosimendan Use After Lung Transplantation
- Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome (PHASE4)
- Comparison Between Levosimendan and Adrenaline in CABG Patients (NA)
- Assessment of Hemodynamic Response in Cardiopulmonary Bypass Graft After Cardiopulmonary Bypass Using Transesophegeal Echocardiography (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- epinephrine and levosimendan CI brief — competitive landscape report
- epinephrine and levosimendan updates RSS · CI watch RSS
- Federal University of Juiz de Fora portfolio CI